共 50 条
- [1] EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2-metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic settingCANCER RESEARCH, 2023, 83 (05)Bardia, AdityaBidard, Francois-ClementNeven, PatrickStreich, GuillermoMontero, Alberto J.Forget, FredericMouret-Reynier, Marie-AngeSohn, Joo HyukTaylor, DonatienneHarnden, Kathleen K.Khong, HungKocsis, JuditDalenc, FlorenceDillon, PatrickBabu, SunilWaters, SimonDeleu, InesGarcia-Saenz, Jose AngelBria, EmilioCazzaniga, Marina ElenaAftimos, PhilippeCortes, JavierTonini, GiuliaSahmoud, TarekHabboubi, NassirGrzegorzewski, KrzysztofKaklamani, Virginia
- [2] Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical SubgroupsCLINICAL CANCER RESEARCH, 2024, 30 (19) : 4299 - 4309Bardia, AdityaCortes, JavierBidard, Francois-ClementNeven, PatrickGarcia-Saenz, JoseAftimos, PhillipeO'Shaughnessy, JoyceLu, JaniceTonini, GiuliaScartoni, SimonaPaoli, AlessandroBinaschi, MonicaWasserman, TomerKaklamani, Virginia
- [3] Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancerNPJ BREAST CANCER, 2024, 10 (01)Mai, Nicholasdos Anjos, Carlos H.Razavi, PedramSafonov, AntonPatil, SujataChen, YuanDrago, Joshua Z.Modi, ShanuBromberg, Jacqueline F.Dang, Chau T.Liu, DazhiNorton, LarryRobson, MarkChandarlapaty, SaratJhaveri, Komal
- [4] Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET)JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Kaklamani, Virginia G.Bidard, Francois ClementNeven, PatrickMontero, Alberto J.Mouret-Reynier, Marie-AngeSohn, JoohyukTaylor, DonatienneForget, FredericHarnden, Kathleen KiernanKhong, Hung T.Kocsis, JuditDalenc, FlorenceDillon, Patrick MichaelWaters, SimonGarcia-Saenz, Jose A.Aftimos, Philippe GeorgesCortes, JavierScartoni, SimonaHabboubi, NassirBardia, Aditya
- [6] Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trialCANCER RESEARCH, 2022, 82 (04)Bardia, AdityaNeven, PatrickStreich, GuillermoMontero, Alberto J.Forget, FredericMouret-Reynier, Marie-AngeSohn, Joo HyukVuylsteke, PeterHarnden, Kathleen K.Khong, HungKocsis, JuditDalenc, FlorenceKaklamani, VirginiaDillon, PatrickBabu, SunilWaters, SimonDeleu, InesGarcia-Saenz, JoseBria, EmilioCazzaniga, MarinaLu, JaniceAftimos, PhilippeCortes, JavierLiu, ShubinLaurent, DirkConlan, Maureen G.Bidard, Francois-Clement
- [7] EMERALD: A randomized, open label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901) versus investigator's choice (IC) of endocrine therapy (ET) for ER+/HER2-advanced breast cancer (BC) following CDK4/6 inhibitor (CDK4/6i) therapy.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Bardia, AdityaAftimos, Philippe GeorgesJiang, HaiBihani, TeeruAnderson-Villaluz, Alfred T.Conlan, Maureen G.Kaklamani, Virginia G.
- [8] Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2-Metastatic Breast CancerCANCER RESEARCH, 2023, 83 (05)Mayer, Erica L.Ren, YueWagle, NikhilMahtani, ReshmaMa, CynthiaDeMichele, AngelaCristofanilli, MassimoMeisel, JaneMiller, Kathy D.Jolly, TrevorRiley, ElizabethQamar, RubinaSharma, PriyankaReid, SonyaSinclair, NatalieFaggen, MeredithBlock, CarolineKo, NaomiPartridge, AnnChen, Wendy Y.Demeo, Michelle K.Attaya, VictoriaOkpoebo, AmandaLiu, YuanGauthier, EricBurstein, HaroldRegan, MeredithTolaney, Sara
- [9] The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2-metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitorsCANCER RESEARCH, 2022, 82 (04)Kamaraju, SailajaFowler, AmyCheng, Chung YeeChaudhary, Lubna N.Burfeind, JohnRetseck, JanetTevaarwerk, Amye J.Burkard, MarkPaplomata, ElisavetParkes, Amanda M.Jorns, Julie M.Tarima, SergeyYee, DouglasRui, HallgeirLange, CarolSahmoud, TarekWisinski, Kari B.
- [10] AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigationCANCER RESEARCH, 2022, 82 (04)Wander, Seth A.Micalizzi, Douglas S.Dubash, TaronishJuric, DejanSpring, Laura M.Vidula, NeelimaKeenan, JenniferBeeler, MaureenViscosi, EleneChe, DanteFisher, Elizabeth L.Hepp, Rachel A.Moy, BeverlyIsakoff, Steven J.Ellisen, Leif W.Supko, Jeffrey G.Maheswaran, ShyamalaHaber, Daniel A.Bardia, Aditya